Cost-effectiveness of pharmacotherapy for autoimmune hepatitis

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 2, 2006, Pages 145-156

  Heneghan, Michael A ^a   Al Chalabi, Thawab ^a   McFarlane, Ian G ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Autoimmune hepatitis; Azathioprine; Calcineurin inhibitors; Corticosteroids

Indexed keywords

6 METHYLTHIOINOSINE; ABATACEPT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFLAZACORT; FINGOLIMOD; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TSUKUBAENOLIDE; URSODEOXYCHOLIC ACID;

ACNE; AUTOIMMUNE HEPATITIS; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER; CATARACT; CLINICAL PRACTICE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; FACE DEFORMITY; GENOTYPE; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MENTAL DISEASE; MONOTHERAPY; MOON FACE; NAUSEA AND VOMITING; NEUTROPENIA; PANCREATITIS; PHARMACOGENOMICS; REMISSION; REVIEW; SURVIVAL TIME; TREATMENT FAILURE; WEIGHT GAIN;

EID: 33144490304     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.2.145     Document Type: Review

References (59)

1. INTERNATIONAL AUTOIMMUNE HEPATITIS GROUP REPORT: Review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. (1999) 31:929-938.
2. VERGANI D, CHOUDHURI K, BOGDANOS DP. MIELI-VERGANI G: Pathogenesis of autoimmune hepatitis. Clin. Liver Dis. (2002) 6:439-449.
3. DONALDSON PT, DOHERTY DG, HAYLLAR KM, MCFARLANE IG, JOHNSON PJ, WILLIAMS R: Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology (1991) 13:701-706.
4. STRETTELL MD, DONALDSON PT THOMSON LJ et al: Allelic basis for HLA-encoded susceptibility to Type 1 autoimmune hepatitis. Gastroenterology (1997) 112:2028-2035.
5. CZAJA AJ, STRETTELL MD, THOMSON LJ et al.: Associations between alleles of the major histocompatibility complex and Type 1 autoimmune hepatitis. Hepatology (1997) 25:317-323.
6. TODA G, ZENIYA M, WATANABE R et al: Present status of autoimmune hepatitis in Japan - correlating the characteristics with international criteria in an area with a high rate of HCV infection. J. Hepatol. (1997) 26:1207-1212.
7. DONALDSON PT, CZAJA AJ: Genetic effects on susceptibility, clinical expression, and treatment outcome of Type 1 autoimmune hepatitis. Clin. Liver Dis. (2002) 6:419-437.
8. GORDON SC: Diagnostic criteria, clinical manifestations and natural history of autoimmune hepatitis. In: Autoimmune Liver Diseases, 2nd edn. Krawitt EL, Wiesner RH, Nishioka M (Eds), Elsevier, Amsterdam, (1998):343-360.
9. MCFARLANE IG: Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. Clin. Liver Dis. (2002) 6:317-333.
10. LUDWIG J, McFARLANE IG, RAKELA J: International Working Party Report: terminology of chronic hepatitis. Am. J. Gastroenterol. (1995) 90:181-189.
11. CZAJA AJ: Treatment of autoimmune hepatitis. In: Autoimmune Liver Diseases, 2nd edn. Krawitt EL, Wiesner RH, Nishioka M (Eds), Elsevier, Amsterdam, (1998):499-515.
12. HENEGHAN MA, MCFARLANE IG: Current and novel immunosuppressive therapy for autoinumme hepatitis. Hepatology (2002) 35:7-13.
13. COOK GC, MULLIGAN R, SHERLOCK S: Controlled prospective trial of corticosteroid therapy in chronic active hepatitis. Quart. J. Med. (1971) 158:159-185.
14. SOLOWAY RD, SUMMERSKILL WH, BAGGENSTOSS AH et al: Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology (1972) 63:820-833.
15. COPENHAGEN STUDY GROUP FOR LIVER DISEASES: Effect of prednisone on the survival of patients with cirrhosis of the liver. Lancet (1969) i:119-121.
16. MURRAY-LYON IM, STERN RB, WILLIAMS R: Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) i:735-737.
17. SCHVARZ R, GLAUMANN H, WEILAND O: Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J. Hepatol, (1993) 18:15-23.
18. ROBERTS SK, THERNEAU TM, CZAJA AJ: Prognosis of histological cirrhosis in Type 1 autoimmune hepatitis. Gastroenterology (1996) 110:848-857.
19. KANZLER S, GERKEN G, LÖHR H, GALLE PR, MEYER ZUM BUSCHENFELDE K-H, LOHSE AW: Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol. (2001) 34:354-355.
20. DUFOUR JF, DELELLIS R, KAPLAN MM: Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann. Intern. Med. (1997) 127:981-985.
21. COTLER SJ, JAKATE S, JENSEN DM: Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin. Gastroenterol. (2001) 32:428-430.
22. SANCHEZ-URDAZPAL L, CZAJA AJ, VAN HOEK B, KROM RA, WIESNER RH: Prognostic features and role of liver transplantation in severe corticosteroid-treatcd autoimmune chronic active hepatitis. Hepatology (1992) 15:215-221.
23. KIRK AP, JAIN S, POCOCK S, THOMAS HC, SHERLOCK S: Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut (1980) 21:78-83.
24. YARZE JC, MEYER ZUM BUSCHENFELDE K-H, LOHSE AW. Autoimmune hepatitis. N. Engl. J. Med. (1996) 334:923-924.
25. HENEGHAN MA. NORRIS SM, O'GRADY JG, HARRISON PM, MCFARLANE IG: Management and outcome of pregnancy in autoimmune hepatitis. Gut (2001) 48:97-102.
26. JOHNSON PJ: Immunosuppressive drug mechanisms. In: Molecular Basis of Autoimmune Hepatitis. McFarlane IG, Williams R (Eds), RG Landes Co., Austin, Texas (1996):177-191.
27. LENNARD L: Clinical implications of thiopurine methyltransferase - optimization of drug dosage and potential drug interactions. Therap. Drug Monit. (1998) 20:527-531.
28. LANGLEY PG, UNDERHILL J, TREDGER JM, NORRIS S, MCFARLANE IG: Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J. Hepatol. (2002) 37:441-447.
29. RUMBO C, EMERICK KM, EMRE S, SHNEIDER BL: Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J. Pediatr. Gastroenterol. Nutr. (2002) 35:391-398.
30. HENEGHAN MA, ALLAN ML, BORNSTEIN JD, MUIR AJ, TENDLER DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of 6-thioguanine metabolites in the management of autoimmune hepatitis. Hepatology (2003) 38(Suppl. 1):489A.
31. PHILLIPS KA, VAN BEBBER SL: A systematic review of cost-effectiveness analyses of pharmacologic interventions. Pharmacogenomics (2004) 5:1139-1149.
32. MARRA CA, ESDAILE JM, ANIS AH: Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J. Rheumatol. (2002) 29:2507-2512.
33. HEGARTY JE, NOURI ARIA KT, PORTMANN B, EDDLESTON AL, WILLIAMS R: Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatolqy (1983) 3:685-689.
34. JOHNSON PJ, McFARLANE IG, WILLIAMS R: Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N. Engl. J. Med. (1995) 333:958-963.
35. STELLON AJ, HEGARTY JE, PORTMANN B, WILLIAMS R: Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet (1985) 1:668-670.
36. STELLON AJ, KEATING JJ, JOHNSON PJ, MCFARLANE IG, WILLIAMS R: Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology (1988) 8:781-784.
37. CZAJA AJ: Treatment strategies in autoimmune hepatitis. Clin. Liver Dis. (2002) 6:511-536.
38. MISTILIS SP, VICKERS CR, DARROCK MH et al.: Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med. J. Aust. (1985) 143:463-465.
39. HYAMS JH, BALLOW M, LEICHTAUER AM: Cyclosporin treatment of autoimmune chronic active hepatitis. Gastroenterology (1987) 93:890-893.
40. PERSON JL, MCHUTCHISON JG, FONG TL, REDEKER AG: A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin. Gastroenterol. (1993) 17:317-320.
41. SHERMAN KE, NARKEWICZ M, PINTO PC: Cyclosporine in the management of corticosteroid-resistant Type I autoimmune chronic active hepatitis. J. Hepatol. (1994) 21:1040-1047.
42. JACKSON LD, SONG E: Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut (1995) 36:459-461.
43. FERNANDES NF, REDEKER AG, VIERLING JM, VILLAMIL FG, FONG TL: Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am. J. Gastroenterol. (1999) 94:241-248.
44. MALEKZADEH R, NASSERI-MOGHADDAM S, KAVIANI MJ, TAHERI H, KAMALIAN N, SOTOUDEH M: Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig. Dis. Sci. (2001) 46:1321-1327.
45. ALVAREZ F, CIOCCA M, CANERO-VELASCO C et al: Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J. Hepatol. (1999) 30:222-227.
46. DEBRAY D, MAGGIORE G, GIRARDET JP, MALLET E, BERNARD O: Efficacy of cyclosporin A in children with Type 2 autoimmune hepatitis. J. Pediatr. (1999) 135:111-114.
47. SCIVERES M, CAPRAI S, PALLA G, UGHI C, MAGGIORE G: Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents. Aliment. Pharmacol. Ther. (2004) 19:209-217.
48. VAN THIEL DH, WRIGHT H, CARROLL P et al: Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am. J. Gastroenterol. (1995) 90:771-776.
49. HENEGHAN MA. RIZZI P, MCFARLANE IG, PORTMANN B, HARRISON PM: Low dose tacrolimus as treatment of severe autoimmune hepatitis: potential role in remission induction. Gut (1999) 44(Suppl. 1):A61.
50. DANIELSSON A, PRYTZ H: Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment. Pharmacol. Ther. (1994) 8:585-590.
51. CZAJA AJ, LINDOR KD: Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology (2000) 119:1312-1316.
52. REBOLLO BERNARDEZ J, CIFUENTES MIMOSO C, PINAR MORENO A et al: Deflazacort for long-term maintenance of remission in Type 1 autoimmune hepatitis. Rev. Esp. Enferm. Dig. (1999) 91:630-638.
53. RICHARDSON PD, JAMES PD, RYDER SD: Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J. Hepatol (2000) 33:371-375.
54. ADAMS A, GISH R, WAKIL E, BZOWEJ N, DOO E, BONACINI M: Mycophenolate mofetil improves liver tests in patients with autoimmune hepatitis (AIH). Hepatology (2003) 38(Suppl.1):490A.
55. DEVLIN, SM, SWAIN MG, URBANSKI SJ, BURAK KW: Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can. J. Gastroenterol. (2004) 18:321-326.
56. BRUNT EM, DI BISCEGLIE AM: Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis. Hum. Pathol. (2004) 35:509-512.
57. KANZLER S, GERKEN G, DIENES HP, MEYER ZUM BUSCHENFELDE KH, LOHSE AW: Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z. Gastroenterol. (1997) 35:571-578.
58. BURAK KW, URBANSKI SJ, SWAIN MG: Successful treatment of refractory Type 1 autoimmune hepatitis with methotrexate. J. Hepatol. (1998) 29:990-993.
59. HENEGHAN MA, MCFARLANE IG: Of mice and women: toward a mouse model of autoimmune hepatitis. Hepatology (2005) 42:17-20.